MedTrace Logo

Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

NCT00655993 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-04-26

No results posted yet for this study

Summary

Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.

Conditions

Interventions

DRUG

simvastatin

40 mg po daily

Sponsors & Collaborators

  • VA Loma Linda Health Care System

    lead FED

Principal Investigators

  • Lennard Specht, M.D. · VA Loma Linda Health Care System

  • Hemal J. Parekh, M.D. · VA Loma LInda Healthcare System

  • James D. Anholm, M.D. · VA Loma Linda Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-03-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655993 on ClinicalTrials.gov